Rifaximin for Preventing Progression and Complications in Patients With Decompensated Liver Cirrhosis
NCT05863364
·
clinicaltrials.gov ↗
NA
Phase
UNKNOWN
Status
150
Enrollment
OTHER
Sponsor class
Conditions
Decompensated Cirrhosis
Interventions
DRUG:
Low-dose of Rifaximin
DRUG:
Conventional dose of Rifaximin
Sponsor
Xin Zeng